Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin’s lymphoma and multiple myeloma

Abstract: Multiple myeloma and non-Hodgkin’s lymphoma remain the most common indications for high-dose chemotherapy and autologous peripheral blood stem cell rescue. While a CD34+ cell dose of $1 \times 10^6$/kg is considered the minimum required for engraftment, higher CD34+ doses correlate with improved outcome. Numerous studies, however, support targeting a minimum CD34+ cell dose of $2.0 \times 10^6$/kg, and an “optimal” dose of $4 \times 6.0 \times 10^6$/kg for a single transplant. Unfortunately, up to 40% of patients fail to mobilize an optimal CD34+ cell dose using myeloid growth factors alone. Plerixafor is a novel reversible inhibitor of CXCR4 that significantly increases the mobilization and collection of higher numbers of hematopoietic progenitor cells. Two randomized multi-center clinical trials in patients with non-Hodgkin’s lymphoma and multiple myeloma have demonstrated that the addition of plerixafor to granulocyte-colony stimulating factor increases the mobilization and yield of CD34+ cells in fewer apheresis days, which results in durable engraftment. This review summarizes the pharmacology and evidence for the clinical efficacy of plerixafor in mobilizing hematopoietic stem and progenitor cells, and discusses potential ways to utilize plerixafor in a cost-effective manner in patients with these diseases.

Keywords: plerixafor, mobilization, stem cells, lymphoma, myeloma

Introduction

High-dose chemotherapy with autologous stem cell transplantation (ASCT) remains an important treatment modality for patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). For patients with aggressive NHL, mostly diffuse large B cell lymphoma, only 40% can be expected to remain disease-free after completing primary chemotherapy.1 However, few patients with relapsed disease can be cured with conventional dose chemotherapy. For the majority of patients who relapse, ASCT remains the best curative option, particularly for patients with chemotherapy-sensitive disease, 40% to 50% of whom remain disease free.2–4 For patients with MM, while not curative, ASCT is associated with the highest complete remission rate, and improved progression-free and overall survival compared with convention chemotherapy.5–7 Furthermore, at least a subset of MM patients, who achieve less than a very good partial response, may benefit from tandem ASCT.8,9 While the role of ASCT in the context of treatment with novel antimyeloma drugs (such as lenalidomide and bortezomib), is debated and requires reinvestigation, it is expected that high-dose therapy...
with ASCT will remain an important part of front-line and relapsed MM for some years. Indeed, the best reported results for MM patients are with tandem cycles of high-dose chemotherapy with ASCT plus novel ant-myeloma agents.\textsuperscript{10,11} Today, MM and NHL remain the most common indications for high-dose chemotherapy with ASCT.\textsuperscript{12}

Autologous hematopoietic stem and progenitor cells (HSPC) are infused following high-dose chemotherapy to mitigate prolonged or permanent myelosuppression, and can be harvested from the bone marrow or collected from peripheral blood by apheresis. The number of stem cells circulating in the peripheral blood, as defined by the number of CD34\textsuperscript{+} cells, however, accounts for <0.06\% of white blood cells.\textsuperscript{13,14} Therefore, CD34\textsuperscript{+} cells residing in the bone marrow have to be mobilized into the circulation prior to apheresis. Over the past 2 decades, mobilized autologous peripheral blood stem cells (PBSC) have replaced bone marrow as the source of hematopoietic stem cells following high-dose chemotherapy, offering a number of advantages over bone marrow harvesting. Infusion of PBSC is associated with significantly shorter durations of neutropenia and thrombocytopenia, reduction in platelet transfusions, faster times to engraftment, and fewer days of hospitalization.\textsuperscript{15–17} Apheresis of PBSC is less invasive than bone marrow harvesting, and results in a significantly higher yield of CD34\textsuperscript{+} cells.

The yield of CD34\textsuperscript{+} cells and the number of aphereses required for successful collection, however, is largely determined by the efficiency of stem cell mobilization. In addition, a number of studies have shown a significant correlation between CD34\textsuperscript{+} cell dose and rapidity of engraftment following high-dose chemotherapy.\textsuperscript{18}

The myeloid growth factors granulocyte macrophage-colony stimulating factor (GM-CSF) and more commonly granulocyte-colony stimulating factor (G-CSF) have been used either alone or in combination with chemotherapy in different mobilization strategies.\textsuperscript{16} Both are approved for mobilizing PBSC. However, because a significant number of patients fail to mobilize sufficient PBSC with growth factors, particularly those requiring tandem cycles of high-dose chemotherapy,\textsuperscript{8,9} there has been increasing interest in methods to improve the yield of mobilized CD34\textsuperscript{+} cells. The CXCR4 antagonist plerixafor is the first noncytokine small molecule recently approved for mobilization of PBSC in combination with G-CSF in patients with NHL and MM. In the following sections, we summarize the current role of plerixafor for increasing mobilization of PBSC and discuss potential directions for its future use.

Cell dose requirement for autologous PBSC transplantation

Defining an optimal CD34\textsuperscript{+} target stem cell dose is important for identifying patients who mobilize poorly with current mobilizing strategies. The number of aphereses used to achieve the target cell dose also complicates the issue. In addition, it is possible that cells other than CD34\textsuperscript{+} cells in mobilized PBSC products may affect outcome beyond engraftment. Therefore, the optimal cell dose requirement for autologous transplantation remains uncertain.

While the minimum safest cell dose to provide engraftment appears to be 1.0 to 1.5 $\times 10^6$ CD34\textsuperscript{+} cells/kg, delayed engraftment, particularly of platelets, is common, indicating that higher doses should be used.\textsuperscript{19,20} In 243 patients with NHL, MM, breast cancer and other solid tumors undergoing ASCT, the number of CD34\textsuperscript{+} cells infused significantly affected the kinetics of neutrophil and platelet engraftment.\textsuperscript{21} CD34\textsuperscript{+} cell doses $\geq 2.5$ $\times 10^6$/kg resulted in more rapid neutrophil engraftment compared with lower doses, although no significant difference in neutrophil recovery was observed between doses of 2.5 to 5.0 $\times 10^6$/kg and $>5.0$ $\times 10^6$/kg.\textsuperscript{21} The kinetics of platelet recovery, however, appeared more affected by higher doses of CD34\textsuperscript{+} cells. Patients receiving $<2.5$ $\times 10^6$ CD34\textsuperscript{+} cells/kg had a significant delay in achieving platelet transfusion independence compared with patients receiving 2.5 to 5.0 $\times 10^6$ CD34\textsuperscript{+} cells/kg, and patients in this intermediate dose group had slower recovery compared with those receiving $>5.0$ $\times 10^6$ CD34\textsuperscript{+} cells/kg.\textsuperscript{21} Similar results were also reported in a larger analysis of 692 patients.\textsuperscript{22} Ninety-five percent of patients who received $\geq 2.5$ $\times 10^6$ CD34\textsuperscript{+} cells/kg achieved neutrophil recovery by day 18 post-transplant, although an incremental improvement in neutrophil recovery was observed with increased numbers of CD34\textsuperscript{+} cells, with “optimal” CD34\textsuperscript{+} cell doses likely to be greater as evidenced by 95\% probabilities of neutrophil recovery at 15 and 13 days post-transplant in patients receiving $\geq 5.0$ or 7.5 $\times 10^6$ CD34\textsuperscript{+} cells/kg, respectively.\textsuperscript{22} Similarly, for platelet recovery to $\geq 20$ $\times 10^9$/L, a CD34\textsuperscript{+} cell dose $\geq 5.0$ $\times 10^6$/kg appeared to be “optimal”, although doses $>12$ $\times 10^6$ CD34\textsuperscript{+} cells/kg resulted in faster recovery.\textsuperscript{22}

Of note in the latter study, patients who required 2 apheresis procedures to collect $>2.5$ $\times 10^6$ CD34\textsuperscript{+} cells/kg had slower platelet engraftment independent of the CD34\textsuperscript{+} cells dose, suggesting that qualitative differences in CD34\textsuperscript{+} cells collected may be important.\textsuperscript{22} While other studies have shown that very high doses of CD34\textsuperscript{+} cells ($>$15 $\times 10^6$/kg) can significantly reduce or eliminate severe thrombocytopenia...
and platelet transfusion requirements. It remains uncertain whether this additional benefit is outweighed by the increased resources required to collect such a large number of progenitors. Collectively, these data have been used to support practice patterns targeting a minimal CD34+ cell dose of 2.0 x 10^6/kg, and an “optimal” dose of 4 to 6 x 10^6/kg for a single transplant.

There is emerging evidence that the immune cell content of mobilized PBSC products also affects autologous transplant outcomes. Patients achieving higher absolute lymphocyte counts by day 15 or 30 after ASCT have significantly longer survival. Furthermore, the early recovery of lymphocytes after transplantation is related to the lymphocyte content of the infused HSPC product, including natural killer cells and CD8+ lymphocytes. Similarly, higher levels of CD80+ dendritic cells in the graft may be associated with improved survival. While these observations require confirmation, they have important implications for mobilization strategies. For example, G-CSF mobilized PBSC contain more lymphocytes compared with G-CSF plus cyclophosphamide mobilized products. Sargramostin (recombinant GM-CSF produced in yeast) plus cyclophosphamide mobilizes significantly more CD80+ dendritic cells compared with cyclophosphamide plus G-CSF. As discussed below, plerixafor also affects the immune cell content of the mobilized cell product and, therefore, might have a significant impact on long-term outcome of autologous transplantation.

Poor mobilization: risk factors and definitions

Clinical risk factors associated with impaired mobilization of stem cells

Several patient characteristics have been associated with reduced PBSC mobilization (Table 1); however these depend on the population studied. Also, for some factors it is not known whether they independently predict reduced mobilization, as not all factors have been included in multivariable analyses. Older age has been associated with poor mobilization in lymphoma and MM patients in some studies, but not in others. Among nearly 1000 MM patients, <12 months of prior therapy, a platelet count >200 x 10^9/L, and lower age were predictive of successful mobilization. In other studies, prior use of melphalan, interferon, and radiation therapy, elevated serum lactate dehydrogenase, renal impairment, and lower albumin level were associated with reduced mobilization.

Prolonged use of lenalidomide is consistently associated with failure to mobilize, particularly with G-CSF alone. Among patients receiving 3 or more cycles of lenalidomide, 25% failed to mobilize. The risk of mobilization failure is also related to the duration of prior treatment with lenalidomide. The failure to mobilize sufficient CD34+ cells after lenalidomide, however, may be largely overcome by mobilization using chemotherapy plus G-CSF. On the other hand, bortezomib does not appear to adversely affect PBSC mobilization.

Among NHL patients, the type and extent of prior chemotherapy are important factors affecting CD34+ cell mobilization. Fludarabine is commonly used for treatment of indolent NHL and has been shown to severely affect PBSC mobilization. In addition, platinum- and etoposide-based regimens commonly used for salvage therapy increase the risk of mobilization failure. Age ≥60 years, platelet count <150 x 10^9/L, and marrow cellularity <30% negatively affect PBSC mobilization. More recently, elevated serum ferritin levels have also been found to impair mobilization in both lymphoma and myeloma patients.

While many of the above risk factors have been associated with poor mobilization, their utility in making clinical decisions is somewhat limited, as their ability to predict patients who will need additional strategies remains imprecise. Similarly, molecular biomarkers such as lower plasma levels of FLT-3, higher plasma stromal cell derived factor-1α (SDF-1α) levels, and higher CXCR4 expression on circulating CD34+ cells have been associated with poor mobilization, although prospective studies are needed to better define their role in identifying patients who might be difficult to mobilize.

### Table 1 Factors associated with poor mobilization of stem cells in multiple myeloma and non-Hodgkin’s lymphoma patients

| Multiple myeloma | Non-Hodgkin’s lymphoma |
|------------------|------------------------|
| Older age        | Older age              |
| More than 12 months of prior therapy | Platelet count <150 x 10^9/L |
| Platelets count <200 x 10^9/L | Bone marrow cellularity <30% |
| Prior chemotherapy | Prior chemotherapy |
| Melphalan         | Fludarabine           |
| Interferon-α      | Platinum compounds    |
| Lenalidomide      | DHAP                   |
| Prior radiation therapy | Elevated serum ferritin |
| Elevated LDH      |                        |
| Renal insufficiency|                        |
| Low albumin       |                        |

Abbreviations: DHAP, dexamethasone, doxorubicin, cytarabine and cisplatin; LDH, lactate dehydrogenase.
Definition of poor mobilization of stem cells

The proportion of patients eligible for ASCT who fail to mobilize an adequate number of CD34+ cells using myeloid growth factors has been variably reported between 5% and 40%, reflecting at least in part a lack of consensus on the definition of “poor mobilizers”. Poor mobilization has been variably defined based on CD34+ cell yield in apheresis products and/or on circulating CD34+ cells following cytokine stimulation. Confounding the definition, a graft anticipated to provide adequate recovery of marrow function at one center may be considered unacceptable in another.59 For example, failure to reach target CD34+ cell yields between 1 and 3 × 10^6/kg have defined products unsuitable at individual centers.60–63 In addition, the number of aphereses and the blood volume processed also affect the CD34+ cell yield. While some centers perform several apheresis procedures if needed to collect the target number of CD34+ cells,64 others do not;65 and the blood volume processed for each collection has varied from 7 to 35 L.64,65 In one suggested classification based on CD34+ cell yield, patients collecting >5 × 10^6 CD34+ cells/kg after multiple aphereses were classified as easily mobilizable; those collecting 1 to 5 × 10^6 CD34+ cells/kg as difficult to mobilize; and those collecting <1 × 10^6 CD34+ cells/kg as nonmobilizable.66

While definitions of poor mobilizers based on CD34+ cell yield may be useful for developing endpoints for clinical trials, cell yield is estimated retrospectively after leukapheresis and does not permit early intervention strategies with the advent of new mobilizing agents such as plerixafor (see below). More recently, a retrospective analysis of 840 NHL and MM patients undergoing PBSC mobilization using cytokines with and without chemotherapy has provided a more precise, and potentially more useful, definition of poor mobilization based on circulating blood CD34+ cell counts after maximal G-CSF stimulation,67 which correlate well with total CD34+ cells collected after 1 to 3 apheresis procedures.13,14 Patients with blood CD34+ cell counts <20/μL, comprising 15.3% of those studied, were considered poor mobilizers. Patients with CD34+ cell levels between 11 and 19/μL were defined as “borderline” poor mobilizers (4.5%), those with CD34+ cell levels between 6 and 10/μL defined as “relative” poor mobilizers (5.8%), and those with CD34+ cell levels ≤5/μL were defined as “absolute” poor mobilizers (5.0%).67 Importantly, all good and “borderline” poor mobilizers achieved the collection goal of 2.0 × 10^6 CD34+ cells/kg after apheresis, although a greater number of aphereses were required. On the other hand, only 77% of “relative” and 40% of “absolute” poor mobilizers achieved the collection goal, albeit with multiple aphereses.67 The definition of poor mobilizers in this way enables early identification of patients who are likely to mobilize poorly and prediction of those who may benefit from intervention using new mobilization strategies.

Plerixafor

Pharmacology and pharmacokinetics: metabolism, distribution, and excretion

Plerixafor (AMD-3100)(1′-[1,4-phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane) (C_{28}H_{54}N_{8}; MW 502.79 g/mol) is a bicyclam (Figure 1) that reversibly blocks binding of SDF-1α to its cognate receptor CXCR4,68,69 an interaction critical to hematopoietic cell trafficking.70,71 Plerixafor was originally developed for the treatment of human immunodeficiency virus (HIV) infection as it was found to inhibit HIV-1 and HIV-2 viral replication. Plerixafor inhibits virus-cell entry by blocking CXCR4, which interacts with envelope glycoprotein gp120 of T lymphotropic HIV strains, leading to fusion of viral and cell membranes.72 In initial phase I trials with plerixafor conducted as a prelude to investigation in HIV patients, unexpected significant leukocytosis with associated mobilization of hematopoietic progenitor cells was observed.73,74 While the poor oral absorption of plerixafor, related to its high positive charge at physiological pH, has limited its further development as an anti-HIV agent, a number of monocyclam derivatives with better solubility that block CXCR4 are currently under evaluation.75

Stem cells express CXCR4 and bind to stromal cell SDF-1α in the bone marrow niche, which with other adhesion molecules anchor stem cells within the niche.76–78 Mobilization of stem cells from bone marrow to peripheral blood is observed following SDF-1α peptide analogs,79,80 plerixafor,81,82 and the SDF-1 analog Met-SDF-1β,80 clearly indicating that altering SDF-1α/CXCR4 signaling, most likely by CXCR4 receptor downmodulation, enhances

Figure 1 Chemical structure of AMD3100; plerixafor.
Plerixafor is rapidly absorbed following SC injection. In both normal volunteers and patients with NHL and MM, peak plasma concentrations are reached within 30 to 60 minutes independent of dose.\textsuperscript{74} The maximum plasma concentrations of plerixafor follow linear dose-dependent kinetics in the dose range of 40 to 240 µg/kg, reaching average maximum concentrations of 121 to 854 ng/mL.\textsuperscript{90} Similarly, dose-dependent kinetics for the area under the curve (AUC) are also observed, with AUC from zero to 10 hours (AUC\textsubscript{0-10}) ranging from averages of 397 to 3183 ng/h/mL following 40 to 240 µg/kg doses. In a population pharmacokinetic analysis in volunteers and patients, a two-compartment disposition model with first order absorption and elimination was found to best describe the plerixafor concentration-time profile. The distribution half-life (t\textsubscript{1/2α}) was estimated to be 0.3 hours with a terminal population half-life (t\textsubscript{1/2β}) of 5.3 hours in subjects with normal renal function. The apparent volume of distribution of plerixafor in healthy human volunteers is 0.28 to 0.33 L/kg after a single SC dose in the dose ranges 40 to 240 µg/kg, and is similar in patients with MM and NHL,\textsuperscript{92} indicating that it is largely confined to the extravascular fluid space and not metabolized.

Plerixafor is mainly eliminated through renal excretion without hepatic metabolism. Approximately 70% of the dose is excreted unchanged in the urine during the first 24 hours. A phase I pharmacokinetic study in otherwise healthy subjects with varying degrees of renal impairment showed an inverse correlation between plerixafor clearance and renal function as determined by the creatinine clearance (CrCl).\textsuperscript{93} Compared to controls (CrCl > 90 mL/min) the mean AUC from time 0 to 24 hours of plerixafor was 7%, 32%, and 39% higher in subjects with mild (CrCl 51–80 mL/min), moderate (CrCl 31–50 mL/min), and severe (CrCl < 31 mL/min, not requiring dialysis) renal insufficiency, respectively, following a single dose of 240 µg/kg.\textsuperscript{93} Since some MM patients requiring ASCT have renal impairment, these data indicate the need for dose reduction in patients with moderate to severe renal insufficiency. A plerixafor dose reduction to 160 µg/kg in patients with CrCl ≤ 50 mL/min is expected to result in exposure similar to a dose of 240 µg/kg in patients with normal or mildly impaired renal function.\textsuperscript{93}

**Clinical efficacy of plerixafor**

The vast majority of studies have investigated the efficacy of plerixafor in enhancing PBSC mobilization after 4 days of G-CSF. An initial phase II trial randomized 25 patients with MM and NHL to receive 10 µg/kg/day G-CSF, starting 4 days before apheresis, with or without 240 µg/kg plerixafor 6 hours before each apheresis on subsequent days.\textsuperscript{89} After a 13- to 17-day washout, patients underwent a second mobilization attempt using the opposite regimen. Peripheral blood CD34+ cells increased a median of 2.9-fold (range, 1.1–13) within 6 hours after plerixafor injection, which translated into higher CD34+ cells collected and fewer aphereses. Nine of 25 patients failed to collect ≥2 × 10\textsuperscript{6} CD34+ cells/kg after G-CSF alone, while no patient receiving plerixafor plus G-CSF failed to collect this minimum number regardless of the sequence of the mobilization regimen. Only 8/25 patients mobilized with G-CSF alone collected ≥5 × 10\textsuperscript{6} CD34+ cells/kg, compared with 20/25 patients following G-CSF plus plerixafor.\textsuperscript{93} Compassionate use protocols were approved in the United States and Europe allowing plerixafor to be used in combination with G-CSF in NHL, Hodgkin’s disease, and MM patients who failed to mobilize sufficient CD34+ cells with G-CSF or who were at high risk of failure.\textsuperscript{94–100} Table 2 summarizes results for plerixafor used in patients who are poor mobilizers.

Two randomized, double blind, placebo-controlled, phase III clinical trials in patients requiring ASCT for MM (n = 302)\textsuperscript{101} and NHL (n = 298)\textsuperscript{102} have been reported (summarized in Table 3), leading to FDA approval of plerixafor...
for mobilization of PBSC in combination with G-CSF in patients with these diseases. In both trials, patients were randomized to receive G-CSF for 4 days prior to starting apheresis on the fifth day, or G-CSF 10 $\mu$g/kg/day for 4 days with plerixafor 240 $\mu$g/kg added the night before each apheresis started on the fifth day. A maximum of 4 apheresis procedures was allowed, with 3 blood volumes processed per procedure, to collect the target number of CD34$^+$ cells. In both studies, patients could not have failed previous mobilization and were not at high risk for mobilization failure by virtue of having previously received 2 or more cycles of alkylator-based therapy or radiation for MM patients, lymphomatous involvement of 20% of the bone marrow or pelvic radiation for NHL patients, respectively. Both trials were multicentered, providing confidence that the clinical results may be generalized to populations similar to those included.

In the phase-III trial involving MM patients, the primary endpoint was the proportion of patients who collected $6 \times 10^6$ CD34$^+$ cells/kg in 2 apheresis days or less. Secondary endpoints included the proportion of patients who collected $5 \times 10^6$ CD34$^+$ cells/kg within 4 aphereses, the number of apheresis days required to reach $6 \times 10^6$ CD34$^+$ cells/kg, and engraftment kinetics. G-CSF plus

#### Table 2

| N | Diagnoses         | No. (%) collecting $2 \times 10^6$ CD34$^+$ cells/kg | Comment                                                                                     |
|---|-------------------|------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Worel et al95 | 27 NHL, HD, MM    | 17 (63%)                                             | Patients previously failed mobilization attempt                                                |
| D’Addio et al96 | 13 MM              | 13 (100%)                                            | Patients failed previous mobilization with chemotherapy plus G-CSF                             |
| Duarte et al97 | 56 NHL, MM        | 42 (75%)                                             | Patients failed previous mobilization with chemotherapy plus G-CSF, G-CSF alone, or G-CSF + stem cell factor |
| Calandra et al94 | 115 NHL, HD, MM    | 60 (60%), 77% (77%), 65 (71%)                        | Patients previously failed mobilization with chemotherapy + G-CSF or G-CSF alone              |
| Tricot et al98 | 20 MM              | Group A: 7 (70%), Group B: 8 (80%)                   | Group A (n = 10): patients previously failed mobilation                                      |
| Hubel et al99  | 47 NHL, MM        | 36 (77%)                                             | Group B (n = 10): patients predicted to be poor mobilizers based on risk factors          |
| Basak et al100 | 61 NHL, HD, MM    | 40 (66%)                                             | Patients previously failed mobilization (n = 51), or predicted to be poor mobilizers based on risk factors (n = 9) |

**Abbreviations:** G-CSF, granulocyte-colony stimulating factor; HD, Hodgkin’s disease; NHL, non-Hodgkin’s lymphoma; MM, multiple myeloma.

#### Table 3

|                         | Multiple myeloma $^{(10)}$ | Non-Hodgkin’s lymphoma $^{(12)}$ |
|-------------------------|----------------------------|----------------------------------|
|                         | Plerixafor + G-CSF (n = 148) | Placebo + G-CSF (n = 154)        | Plerixafor + G-CSF (n = 150) | Placebo + G-CSF (n = 148) |
| Patients meeting primary endpoint (%) $^a$ | 71.6                        | 34.4                             | 59.3                        | 19.6                        |
| Estimated percent patients collecting target CD34 cell dose $^b$ |                          |                                 |                             |                             |
| Day 1 apheresis         | 54.2                        | 17.3                             | 27.9                        | 4.2                          |
| Day 2 apheresis         | 77.9                        | 35.3                             | 49.1                        | 14.2                         |
| Day 3 apheresis         | 86.8                        | 48.0                             | 57.7                        | 21.6                         |
| Day 4 apheresis         | 86.8                        | 55.9                             | 65.6                        | 24.2                         |
| Patients collecting $\geq 2 \times 10^6$ CD34$^+$ cells/kg in 4 days (%) | 75.7                        | 51.3                             | 86.7                        | 47.3                         |
| Median (range) CD34$^+$ cells collected ($\times 10^6$/kg) | 10.96 (0.66–104.57)       | 6.18 (0.11–42.66)               | 5.69 (0.03–29.22)          | 1.98 (0.06–15.00)            |
| Patients undergoing transplantation (%) | 95.9                        | 88.3                             | 90.0                        | 55.4                         |
| Patients undergoing tandem transplantation (%) | 21.6                        | 15.6                             | NA                          | NA                           |
| Median time to neutrophil engraftment (days) | 11                          | 11                               | 10                          | 10                           |
| Median time to platelet engraftment (days) | 18                          | 18                               | 20                          | 20                           |

**Notes:** $^a$Primary endpoint for MM trial is collection of $6 \times 10^6$ CD34$^+$ cells/kg in 2 apheresis days or less, and for NHL trial is collection of $5 \times 10^6$ CD34$^+$ cells/kg in 4 apheresis days or less. $^b$Kaplan–Meier estimates of proportion of patients collecting $\geq 6 \times 10^6$ CD34$^+$ cells/kg for MM patients, and $\geq 5 \times 10^6$ CD34$^+$ cells/kg for NHL patients. **Abbreviations:** G-CSF, granulocyte-colony stimulating factor; NHL, non-Hodgkin’s lymphoma; MM, multiple myeloma.
plerixafor resulted in more patients yielding ≥6 × 10^6 CD34+ cells/kg within 2 aphereses compared with G-CSF plus placebo (71.6% vs 34.4%; P < 0.001). A median of 1 apheresis day was required to collect ≥6 × 10^6 CD34+ cells/kg with G-CSF plus plerixafor compared with 4 days with G-CSF and placebo (P < 0.001). For the secondary mobilization endpoint, more patients in the plerixafor group collected ≥6 × 10^6 CD34+ cells/kg in four or fewer apheresis days compared to the placebo group (75.7% vs 51.3%; P < 0.001). Patients in the plerixafor group also collected a significantly higher total number of CD34+ cells. All patients receiving plerixafor collected ≥2 × 10^6 CD34+ cells/kg, the minimum to proceed with transplantation, while 4.6% of those mobilized with G-CSF and placebo failed and required rescue mobilization with plerixafor. More MM patients in the plerixafor group received planned tandem transplantations (21.6%) compared with those in the placebo group (15.6%).

In the phase III trial of NHL patients, the primary endpoint of the study was the proportion of patients who collected ≥5 × 10^6 CD34+ cells/kg in 4 apheresis days. Among patients receiving G-CSF plus plerixafor, 59.3% achieved this target compared with 19.6% in the placebo group (P < 0.001). A greater proportion of patients in the plerixafor group also collected at least 2 × 10^6 CD34+ cells/kg in four apheresis days (86.7% vs 47.3%; P < 0.001). The time for collecting the minimum number of CD34+ cells was also achieved in significantly fewer apheresis days. Of 10 patients in the plerixafor group who failed to mobilize, 4 were successfully remobilized with plerixafor and G-CSF in an open label rescue phase of the trial, while 33 of 52 (64%) from the placebo group failing to mobilize achieved ≥2 × 10^6 CD34+ cells/kg following remobilization with plerixafor and G-CSF.

In both randomized trials, engraftment kinetics and durability were reported to be similar for both the plerixafor and placebo groups in patients who underwent transplantation. In a post hoc analysis, there was a significant trend between CD34+ cell dose and the proportion of patients maintaining a platelet count of ≥150 × 10^9/L on and beyond day 100 for NHL patients, but only at day 100 after transplantation for MM patients. While the clinical significance of this finding remains uncertain, it may reflect better marrow reserves in patients who receive a larger dose of CD34+ cells, which, in turn, may result in improved tolerance of subsequent treatments in patients who relapse, particularly those with MM where relapse is almost universal. As noted above, both NHL and MM patients who received plerixafor yielded higher CD34+ cell collections and this may have important implications for subsequent management.

**Side effects and adverse reactions**

Plerixafor is generally safe and well tolerated. In the two randomized trials in patients with MM and NHL, the most common adverse events that were considered related to plerixafor were injection site erythema (20%–29%), fatigue (8%), and gastrointestinal symptoms, including nausea (16%–17%), vomiting (5%), diarrhea (18%–38%), abdominal pain (6%), and flatulence (5%). Mild to moderate systemic reactions including urticaria, periorbital swelling, dyspnea, and hypoxia were observed in <1% of patients approximately 30 minutes after plerixafor administration and responded to treatments or resolved spontaneously. Symptoms were generally mild with good patient compliance and treatment only rarely led to discontinuation of drug. In the MM trial, only 1 patient receiving plerixafor discontinued treatment after 3 doses because of diarrhea and fatigue, and 2 patients in the placebo group discontinued treatment because of an enlarged spleen in 1 patient and nausea, vomiting, and abdominal pain in the other. In the NHL study, no patient discontinued treatment because of plerixafor-related side effects. No interactions of plerixafor with other drugs are known.

**A clinical perspective on the use of plerixafor for mobilization of autologous stem cells**

The safety and efficacy of plerixafor in mobilizing autologous PBSC is clinically proven, and from a scientific perspective, the results support the routine use of plerixafor in combination with G-CSF for mobilizing PBSC in all patients with NHL and MM undergoing ASCT. A significant limitation to routine use of plerixafor, however, remains the cost, particularly as one-third or more of unselected patients will collect an adequate number of CD34+ cells within two apheresis days using G-CSF alone. A US nationwide inpatient sample study recently reported the average cost of an autologous PBSC transplant performed between 2000 and 2001 for NHL and MM patients, including collection and cryopreservation of stem cells, was approximately US$51,000, with significantly higher costs if complications occurred. The wholesale price of a vial (20 mg/1.2 mL) of plerixafor is approximately US$7,500. Therefore, for an average adult, a 2-day course of plerixafor would cost US$15,000. Furthermore, plerixafor plus G-CSF mobilization...
has also been reported to lead to an apheresis product with a lower ratio of CD34+ cells to total nucleated cells, resulting in an increased requirement for storage bags and, in turn, cost of PBSC storage.\textsuperscript{106} A cost-effectiveness analysis demonstrating that the high cost of plerixafor can be offset by a decreased number of aphereses required to collect a target CD34+ cell dose is likely required before routine use of plerixafor can be recommended for all patients. While one study has shown that the cost of plerixafor plus G-CSF mobilization is similar to that of cyclophosphamide and G-CSF mobilization with less morbidity,\textsuperscript{107} an analysis comparing with G-CSF alone is not currently available.

An alternative, and possibly more cost effective strategy, may be to reserve the use of plerixafor to patients who are “poor mobilizers”. As reviewed above and summarized in Table 2, 63% to 76% of patients who fail to collect a sufficient CD34+ cell dose will collect successfully following a remobilization attempt with G-CSF plus plerixafor. However, such a second mobilization attempt would be expected to significantly add to total cost. While clinical risk factors are significantly associated with mobilization failure, their predictive value is not sufficiently strong. A more practical approach may be to begin mobilization with G-CSF alone in the standard manner, assess peripheral blood CD34+ cell counts on the fourth day of mobilization, and, if the CD34+ cell count is less than 10 to 20/µL, add plerixafor on the evening of the fourth day onward, beginning apheresis on the fifth day as initially planned. The validity of this patient-targeted, decision-making algorithm has recently been shown to be potentially cost saving.\textsuperscript{108,109}

**Future directions**

To date, most research investigating plerixafor for mobilization has largely focused on increasing the number of CD34+ cells mobilized and collected by apheresis compared to G-CSF alone. However, there is increasing data showing that the plerixafor-mobilized PBSC product is also qualitatively different. Plerixafor in combination with G-CSF appears to mobilize more primitive HSPC with higher repopulation potential than G-CSF alone.\textsuperscript{110} Furthermore, HSPC mobilized with plerixafor plus G-CSF have different microRNA and gene expression profiles compared to those mobilized with G-CSF alone.\textsuperscript{111} The clinical significance of these qualitative differences remains unknown.

In addition to HSPC content, the immunological cell composition of apheresis products mobilized with plerixafor requires further investigation. As reviewed above, the lymphocyte and dendritic cell content of PBSC products may significantly affect relapse after ASCT.\textsuperscript{28–30} As PBSC products mobilized following plerixafor have been shown to contain more lymphocytes\textsuperscript{112} and dendritic cells,\textsuperscript{31,113} the ability to modify long-term outcome requires further study. In particular, to further increase dendritic cell content, investigation of the combination of plerixafor and GM-CSF might also be an additional avenue of investigation.

Although plerixafor is approved for use only in NHL and MM patients, a significant proportion of patients with Hodgkin’s disease also mobilize poorly and could be candidates for plerixafor. Such patients were included in the previous series but not in the registration trials of plerixafor. Finally, patients with resistant and relapsed germ cell tumors have a good outcome with tandem ASCT.\textsuperscript{114} Since these patients are usually exposed to platinum drugs in primary therapy, many are difficult to mobilize following G-CSF alone. Investigation of plerixafor in this population is indicated.

Beyond its use in mobilization of HSPC for transplantation, the appreciation that CXCR4 chemokine receptors are expressed by neoplastic cells from patients with acute and chronic leukemias, as well as a variety of solid tumors, has raised interest in the potential therapeutic role of plerixafor in a variety of cancers.\textsuperscript{91,115,116} Within the tumor microenvironment (including outside the bone marrow), the interaction of SDF-1α on stromal cells with CXCR4 on tumor cells has been shown to promote growth and survival signals to a variety of cancer cell types,\textsuperscript{117,118} facilitate tumor progression by recruiting endothelial progenitor cells for tumor angiogenesis,\textsuperscript{118} and confer cell adhesion-mediated drug resistance to both solid tumor cells and leukemia.\textsuperscript{119} By blocking CXCR4-SDF-1α interactions in the microenvironment, a rationale for investigating plerixafor in the treatment of acute myeloid leukemia,\textsuperscript{120–123} BCR-ABL+ leukemia,\textsuperscript{124} chronic lymphocytic leukemia,\textsuperscript{91} mantle cell lymphoma,\textsuperscript{125} multiple myeloma,\textsuperscript{126} breast cancer,\textsuperscript{118} and lung cancer,\textsuperscript{127} has been reported. Clinical investigation of plerixafor in combination with chemotherapeutic agents will be important to determine the efficacy of the novel approach of CXCR4 blockade in the treatment of in these diseases.

**Conclusions**

Plerixafor is a novel small molecule inhibitor of CXCR4 and has been shown to significantly increase the mobilization and collection of higher numbers of PBSC in 2 randomized trials, and is now approved in combination with G-CSF for mobilization in NHL and MM patients undergoing ASCT. Although well tolerated and efficacious, use of plerixafor in all such patients undergoing transplantation is limited by high cost.
Pre-emptive strategies that target only patients who mobilize poorly with G-CSF may result in more cost-effective utilization of plerixafor. Investigation of plerixafor in patient populations other than those approved for its use, including Hodgkin’s disease and patients with germ cell tumors undergoing transplantation, is important, as many of these patients tend to mobilize poorly because of prior therapy. In addition, investigation of qualitative differences in PBSC products mobilized with plerixafor compared with G-CSF alone will lead to better understanding of the significance of graft composition in the autologous setting and may lead to better long-term outcomes in patients undergoing ASCT.

Disclosure
The authors report no conflict of interest in this work.

References
1. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1991;324(14):1002–1006.
2. Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998;16(10):3264–3269.
3. Martelli M, Vignetti M, Zinzani PL, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and etarabine in aggressive non-Hodgkin’s lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol. 1996;14(2):534–542.
4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–1545.
5. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335(2):91–97.
6. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–1883.
7. Palumbo A, Brighenti S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104(10):3052–3057.
8. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495–2502.
9. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25(17):2434–2441.
10. Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol. 2010;28(5):800–807.
11. Van Rhee F, Szymonifka J, Anaisse E, et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative doses and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood. 2010;116(8):1220–1227.
12. Pasquini MC, He K, Perez WS. CIBMTR summary slides part 1. CIBMTR Newsletters. 2006;12:5–7.
13. Fruehauf S, Haas R, Conradt C, et al. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood. 1995;85(9):2619–2626.
14. Fruehauf S, Schmitt K, Veldwijk MR, et al. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol. 1999;105(3):786–794.
15. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;346(8988):353–357.
16. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood. 1997;89(7):2233–2258.
17. Weaver CH, Buckner CD, Curtis LH, et al. Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy. Bone Marrow Transplant. 2002;29(2):159–164.
18. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34+ cell dose in bone cell transplantation for cancer therapy. J Clin Oncol. 2000;18(6):1360–1377.
19. Desikan KR, Tricot G, Munshi NC, et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol. 2001;112(1):242–247.
20. Watts MJ, Sullivan AM, Leverett D, et al. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol. 1998;16(4):1554–1560.
21. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13(10):2547–2555.
22. Weaver CH, Hazeldon B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86(10):3961–3969.
23. Benedetti G, Paito L, Giglietti A, Alessio M, Pelicci P, Grignani F. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients. Bone Marrow Transplant. 1999;24(9):971–979.
24. Ketterer N, Salles G, Raba M, et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood. 1998;91(9):3148–3155.
25. Giralt S, Stadmayer EA, Harousseau JL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009;23(10):1904–1912.
26. Gertz MA, Kumar SK, Lacy MQ, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myelomas. Bone Marrow Transplant. 2009;43(8):619–625.
27. Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarz AP. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma. Cytotherapy. 2008;10(5):507–517.
28. Atta EH, de Azvedo AM, Maiolino A, et al. High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation. Am J Hematol. 2009;84(1):21–28.
29. Portra LF, Markovic SN. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clin Exp Med. 2004;4(2):78–85.
31. Gazitt Y, Callander N, Freytes CO, et al. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin’s lymphoma patients: a randomized prospective study. *J Hematother Stem Cell Res*. 2000;9(5):737–748.

32. Kotasek D, shepherd KM, Sage RE, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. *Bone Marrow Transplant*. 1992;9(11):1–17.

33. Koumakis G, Vassilomanolakis M, Hatzichristou H, et al. Predictive factors affecting mobilization and peripheral blood stem cell (PBSC) collection using single apheresis (SA) for rescuing patients after high-dose chemotherapy (HD.CHE) in various malignancies. *Bone Marrow Transplant*. 1996;18(6):1065–1072.

34. Fietz T, Rieger K, Dimeo F, Blau IW, Thiel E, Knauf WU. Stem cell mobilization in multiple myeloma patients: do we need an age-adjusted regimen for the elderly? *J Clin Apher*. 2004;19(4):202–207.

35. Hosing C, Saliba RM, Ahlawat S, et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. *Am J Hematol*. 2009;84(6):335–337.

36. Canales MA, Fernandez-Jimenez MC, Martin A, et al. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin’s disease. *Haematologica*. 2001;86(5):494–498.

37. Ozkurt ZN, Yegin ZA, Suyani E, et al. Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation. *J Clin Apher*. 2010;25:280–286.

38. Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. *Br J Haematol*. 2003;120(3):413–423.

39. Boccadoro M, Palumbo A, Bringhen S, et al. Oral melphalan at diagnosis of multiple myeloma. *J Hematother Stem Cell Res*. 2002;11:319–329.

40. Putkonen M, Rauhala A, Pelliniemi TT, Remes K. Sepsis, low platelet nadir at mobilization and previous IFN use predict stem cell mobilization failure in patients with multiple myeloma. *Cytotherapy*. 2007;9(6):548–554.

41. Prince HM, Imrie K, Sutherland DR, et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. *Br J Haematol*. 1996;93(1):142–145.

42. Egan K, Singh V, Gidron A, Mehta J. Correlation between serum lactate dehydrogenase and stem cell mobilization. *Bone Marrow Transplant*. 2007;40(10):931–934.

43. Nakasone H, Kanda Y, Ueda T, et al. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma. *Am J Hematol*. 2009;84(12):809–814.

44. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. *Leukemia*. 2007;21(9):1925–1926.

45. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. *Leukemia*. 2008;22(6):1280–1281; author reply 1281–1282.

46. Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. *Biol Blood Marrow Transplant*. 2009;15(6):718–723.

47. Paripati H, Stewart AK, Cabou S, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. *Leukemia*. 2008;22(6):1282–1284.

48. Oakervee H, Popat R, Cavenagh JD. Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment. *Leuk Lymphoma*. 2007;48(10):1910–1921.

49. Laszlo D, Galeni P, Raspadori D, Tozzi M, Lauria F, Martinelli G. Fludarabine combination regimen severely affected peripheral blood stem cell mobilization. *Acta Haematol*. 2004;111(4):228–229.

50. Tournilhac O, Cazin B, Lepretre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. *Blood*. 2004;103(1):363–365.

51. Ford CD, Green W, Warense S, Petersen FB. Effect of prior chemotherapy on hematopoietic stem cell mobilization. *Bone Marrow Transplant*. 2004;33(9):901–905.

52. Olivieri A, Brunori M, Capelli D, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. *Eur J Haematol*. 2004;72(1):10–17.

53. Gazitt Y, Liu Q. High steady-state plasma levels of β3-ligand in the peripheral blood is a good predictor for poor mobilization of CD34+ PBSC in patients undergoing high-dose chemotherapy and stem cell rescue. *J Hematother Stem Cell Res*. 2000;9(2):285–293.

54. Gazitt Y, Liu Q. Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34+ cells in mobilized peripheral blood of non-Hodgkin’s lymphoma patients. *Stem Cells*. 2001;19(1):37–45.

55. Gordan LN, Sugrue MW, Lynch JW, et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. *Leuk Lymphoma*. 2003;44(5):815–820.

56. Pavone V, Gaudio F, Console G, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. *Bone Marrow Transplant*. 2006;37(8):719–724.

57. Akhtar S, Weshi AE, Rahal M, et al. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. *Leuk Lymphoma*. 2008;49(4):769–778.

58. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. *Biol Blood Marrow Transplant*. 2008;14(9):1045–1056.

59. Kessinger A, Sharp JG. The whys and hows of hematopoietic progenitor and stem cell mobilization. *Bone Marrow Transplant*. 2003;31(5):319–329.

60. Watts MJ, Ings SJ, Flynn M, Dodds D, Goldstone AH, Linch DC. Remobilization of patients who fail to achieve minimal progenitor thresholds at the first attempt is clinically worthwhile. *Br J Haematol*. 2000;111(1):287–291.

61. Fraipont V, Sautois B, Baudoux E, et al. Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF. *Transfusion*. 2000;40(3):339–347.

62. Weaver CH, Tauer K, Zhen B, et al. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. *J Hematother*. 1998;7(3):241–249.

63. Bashey A, Corringham S, Gilpin E, et al. Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate initial progenitor cell collections for autologous transplantation. *Cytotherapy*. 2000;2(3):195–200.

64. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. *Blood*. 1988;71(3):723–727.

65. Comenzo RL, Malachowski ME, Miller KB, et al. Large-volume leukapheresis for collection of mononuclear cells for hematopoietic rescue in Hodgkin’s disease. *Transfusion*. 1995;35(1):42–45.

66. Stiff PJ. Management strategies for the hard-to-mobilize patient. *Bone Marrow Transplant*. 1999;23 Suppl 2:S29–S33.
67. Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. *Blood Marrow Transplant*. 2010;16(4):490–499.

68. Gerflach LO, Skerlj RT, Bridger GJ, Schwartz TW. Molecular interactions of cyclin and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. *J Biol Chem*. 2001;276(17):14153–14160.

69. Hatse S, Princen K, Bridger G, De Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. *FEBS Lett*. 2002;527(1–3):255–262.

70. LapidoT, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. *Leukemia*. 2002;16(10):1992–2003.

71. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. *Science*. 1999;283(5403):845–848.

72. Este JA, Telenti A. HIV entry inhibitors. *Lancet*. 2007;369(9581):81–88.

73. De Clercq E. The bicyclam AMD3100 story. *Nat Rev Drug Discov*. 2003;2(7):581–587.

74. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. *Antimicrob Agents Chemother*. 2000;44(6):1667–1673.

75. Pettersson S, Perez-Nueno VI, Mena MP, et al. Novel monocyclam derivatives as HIV entry inhibitors: Design, synthesis, anti-HIV evaluation, and their interaction with the CXCR4 co-receptor. *Chem Med Chem*. 2010;5(8):1272–1281.

76. Nilsson SK, Johnston HM, Coverdale JA. Spatial localization of transplanted hematopoietic stem cells: inferences for the localization of stem cell niches. *Blood*. 2001;97(8):2293–2299.

77. Lord BJ, Testa NG, Hendry JH. The relative spatial distributions of CFUs and CFUc in the normal mouse femur. *Blood*. 1975;46(1):65–72.

78. Lord BJ, Wright EG. Spatial organisation of CFU-S proliferation regulators in the mouse femur. *Leuk Res*. 1984;8(6):1073–1083.

79. Pelus LM, Bion H, Fukuda S, Wong D, Merzouk A, Safari H. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor. *Exp Hematol*. 2005;33(3):295–307.

80. Shen H, Cheng T, Olszak I, et al. CXCR4-4 desensitization is associated with tissue localization of hematopoietic progenitor cells. *J Immunol*. 2001;166(8):5027–5033.

81. Broxmeyer HE, Orcshell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. *J Exp Med*. 2005;201(8):1307–1318.

82. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. *Transfusion*. 2005;45(3):295–300.

83. Burroughs L, Mielcarek M, Little MT, et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. *Blood*. 2005;106(12):4002–4008.

84. Larochelle A, Krouse A, Metzger M, et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. *Blood*. 2006;107(9):3772–3778.

85. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. *Blood*. 2003;102(8):2728–2730.

86. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. *J Clin Oncol*. 2004;22(6):1095–1102.

87. Grignani G, Perissinotto E, Cavalloni G, Carnevale Schianca F, Aglietta M. Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin’s lymphoma or multiple myeloma. *J Clin Oncol*. 2005;23(16):3871–3872; author reply 3872–3873.

88. Pelus LM, Fukuda S. Chemokine-mobilized adult stem cells; defining a better hematopoietic graft. *Leukemia*. 2008;22(3):466–473.

89. Flomenberg N, Devine SM, D’Addio A, et al. The use of AMD3100 plus G-CSF for allogeneic hematopoietic progenitor cell mobilization is superior to G-CSF alone. *Blood*. 2005;106(5):1867–1874.

90. Cashen A, Lopez S, Gao F, et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. *Blood Marrow Transplant*. 2008;14(11):1253–1261.

91. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. *Leukemia*. 2009;23(1):43–52.

92. Stewart DA, Smith C, MacFarland R, Calandra G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. *Blood Marrow Transplant*. 2009;15(1):39–46.

93. MacFarland R, Hard ML, Scarborough R, Badel K, Calandra G. A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. *Blood Marrow Transplant*. 2010;16(1):85–101.

94. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. *Bone Marrow Transplant*. 2008;41(4):331–338.

95. Worel N, Rosskopf K, Neumeister P, et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. *Transfusion*. September 28, 2010 [Epub ahead of print].

96. D’Addio A, Curti A, Worel N, et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. *Bone Marrow Transplant*. May 31, 2010 [Epub ahead of print].

97. Duarte RF, Shaw BE, Marin P, et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. *Bone Marrow Transplant*. March 22, 2010 [Epub ahead of print].

98. Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. *Bone Marrow Transplant*. 2010;45(1):63–68.

99. Hubel K, Fresen MM, Basara N, et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. *Bone Marrow Transplant*. October 25, 2010 [Epub ahead of print].

100. Basak GW, Knopinska-Pusluzny W, Matuszak M, et al. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100): Polish compassionate use program. *Ann Hematol*. 2010;15(4):61–67.

101. DiPersio JF, Stadmayer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. *Blood*. 2009;113(23):5720–5726.

102. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. *J Clin Oncol*. 2009;27(28):4767–4773.
103. Stiff PJ, Micalef IN, Nademanee AP, et al. Transplanted CD34+ cell dose is associated with long-term platelet count following autologous hematopoietic stem cell transplant in patients with non-Hodgkin’s lymphoma and multiple myeloma. *ASH Annual Meeting Abstracts*. 2008;112(5):2175a.

104. Jones JA, Qaziilbash MH, Shih YC, Cantor SB, Cooksley CD, Elting LS. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. *Cancer*. 2008;112(5):1096–1105.

105. PDR. *Red Book: Pharmacy’s Fundamental Reference*. Montvale NJ, editor. Thompson Healthcare; 2009.

106. Tanhehco YC, Adamski J, Sell M, et al. Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs. *J Clin Apher*. 2010;25(4):202–208.

107. Shaughnessy P, Islas-Ohlmayer M, Murphy J, et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. *Biol Blood Marrow Transplant*. August 30, 2010 [Epub ahead of print].

108. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. *Bone Marrow Transplant*. 2011;46(1):64–69.

109. Costa LJ, Miller AN, Alexander ET, et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cell mobilization. *Bone Marrow Transplant*. July 12, 2010 [Epub ahead of print].

110. Fruehauf S, Veldwijk MR, Seeger T, et al. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. *Cytottherapy*. 2009;11(8):992–1001.

111. Jin P, Wang E, Ren J, et al. Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cd expression analysis. *J Transl Med*. 2008;6:39.

112. Devine SM, Vij R, Retig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. *Blood*. 2008;112(4):990–998.

113. Gazit Y, Freytes CO, Akay C, Badel K, Calandra G. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin’s lymphoma patients. *Stem Cells Dev*. 2007;16(4):657–666.

114. Einhorn LH, Williams SD, Channess A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem cell rescue for metastatic germ-cell tumors. *N Engl J Med*. 2007;357(4):340–348.

115. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. *Blood*. 2006;107(5):1761–1767.

116. Burger JA, Burke A. The CXCR4 chemokine receptor in acute and chronic leukemia: a narrow homoing receptor and potential therapeutic target. *Br J Haematol*. 2007;137(4):288–296.

117. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell’Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. *Blood*. 2000;96(8):2655–2663.

118. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell*. 2005;121(3):335–348.

119. Li ZW, Dalton WS. Tumor microenvironment and drug resistance in hematologic malignancies. *Blood Rev*. 2006;20(6):333–342.

120. Jacobi A, Thieme S, Lehmann R, et al. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts. *Exp Hematol*. 2010;38(3):180–190.

121. Liesveld JL, Bechelli J, Rosell K, et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. *Leuk Res*. 2007;31(11):1553–1563.

122. Nervi B, Ramirez P, Retig MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. *Blood*. 2009;113(24):6206–6214.

123. Tavor S, Eisenbach M, Jacob-Hirsch J, et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. *Leukemia*. 2008;22(12):2151–2158.

124. Dillmann F, Veldwijk MR, Laufs S, et al. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib. *Leuk Lymphoma*. 2009;50(10):1676–1686.

125. Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. *Blood*. 2009;113(19):4604–4613.

126. Katz BZ, Tavor S. The stromal derived factor-1/CXCR4 axis–a legitimate therapeutic target in multiple myeloma? *Leuk Lymphoma*. 2009;50(7):1067–1068.

127. Burger JA, Stewart DJ. CXCR4 chemokine receptor antagonists: perspectives in SCLC. *Expert Opin Investig Drugs*. 2009;18(4):481–490.